We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Research Meeting (Suresh Muthukumaraswamy, Cardiff)

Suresh Muthukumaraswamy (Cardiff)

The ability of MEG to non-invasively, directly record neuronal activity with high temporal resolution make MEG a well-suited, but under-exploited, technique for the study of central nervous system drug action in humans. After providing a brief introduction to MEG from a pharmacological perspective, I will present the results of several studies we have conducted. This includes recent studies using, the sedative propofol , the anti-epileptic tiagabine (GABA uptake blocker), and the psychedelic psilocybin (5HT2A agonist). A number of ways to approach pharmaco-MEG data will be considered, including, task-induced activity, resting brain activity, functional connectivity and neuronal mass modeling (DCM). Similarities between the effects seen in our drug studies with our patient group studies (e.g. juvenile myoclonic epilepsy, remitted depression, schizoaffective disorder) will be highlighted.